Adlai Nortye Ltd. American Depositary Shares (ANL) - Net Assets
Based on the latest financial reports, Adlai Nortye Ltd. American Depositary Shares (ANL) has net assets worth $-8.32 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($34.43 Million) and total liabilities ($42.76 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ANL goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-8.32 Million |
| % of Total Assets | -24.17% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 33.31 |
Adlai Nortye Ltd. American Depositary Shares - Net Assets Trend (2019–2025)
This chart illustrates how Adlai Nortye Ltd. American Depositary Shares's net assets have evolved over time, based on quarterly financial data. See ANL days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Adlai Nortye Ltd. American Depositary Shares (2019–2025)
The table below shows the annual net assets of Adlai Nortye Ltd. American Depositary Shares from 2019 to 2025. For live valuation and market cap data, see Adlai Nortye Ltd. American Depositary Sh market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-8.32 Million | -132.65% |
| 2024-12-31 | $25.48 Million | -66.04% |
| 2023-12-31 | $75.05 Million | +131.10% |
| 2022-12-31 | $-241.29 Million | -30.13% |
| 2021-12-31 | $-185.43 Million | -40.95% |
| 2020-12-31 | $-131.56 Million | -89.62% |
| 2019-12-31 | $-69.38 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Adlai Nortye Ltd. American Depositary Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 37822653700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $12.00K | % |
| Other Comprehensive Income | $17.25 Million | % |
| Other Components | $439.27 Million | % |
| Total Equity | $-8.32 Million | 100.00% |
Adlai Nortye Ltd. American Depositary Shares Competitors by Market Cap
The table below lists competitors of Adlai Nortye Ltd. American Depositary Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guolin Environmental Tech Co Ltd
SHE:300786
|
$590.52 Million |
|
Echo Investment SA
WAR:ECH
|
$590.61 Million |
|
Ovzon AB
ST:OVZON
|
$590.76 Million |
|
Grupo Supervielle S.A
F:189A
|
$590.94 Million |
|
JL MAG RARE-EARTH H YC1
F:3KLA
|
$590.10 Million |
|
SmartFinancial, Inc.
NASDAQ:SMBK
|
$590.02 Million |
|
Yoantion Industrial Inc.Ltd.
SHE:301053
|
$590.00 Million |
|
HelloFresh SE
XETRA:HFG
|
$589.85 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Adlai Nortye Ltd. American Depositary Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 25,485,000 to -8,322,035, a change of -33,807,035 (-132.7%).
- Net loss of 35,528,000 reduced equity.
- Other comprehensive income increased equity by 21,781,073.
- Other factors decreased equity by 20,060,108.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-35.53 Million | -426.91% |
| Other Comprehensive Income | $21.78 Million | +261.73% |
| Other Changes | $-20.06 Million | -241.05% |
| Total Change | $- | -132.65% |
Book Value vs Market Value Analysis
This analysis compares Adlai Nortye Ltd. American Depositary Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-8.18 | $10.05 | x |
| 2020-12-31 | $-15.51 | $10.05 | x |
| 2021-12-31 | $-21.87 | $10.05 | x |
| 2022-12-31 | $-28.45 | $10.05 | x |
| 2023-12-31 | $11.03 | $10.05 | x |
| 2024-12-31 | $2.39 | $10.05 | x |
| 2025-12-31 | $-0.78 | $10.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Adlai Nortye Ltd. American Depositary Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -710.56%
- • Asset Turnover: 0.15x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-49.87%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.89 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-50.22 Million |
| 2021 | 0.00% | -123.95% | 0.35x | 0.00x | $-38.14 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-34.66 Million |
| 2023 | -145.55% | -2186.46% | 0.04x | 1.73x | $-116.73 Million |
| 2024 | -203.53% | 0.00% | 0.00x | 2.80x | $-54.42 Million |
| 2025 | 0.00% | -710.56% | 0.15x | 0.00x | $-34.70 Million |
Industry Comparison
This section compares Adlai Nortye Ltd. American Depositary Shares's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $296,451,843
- Average return on equity (ROE) among peers: -36.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Adlai Nortye Ltd. American Depositary Shares (ANL) | $-8.32 Million | 0.00% | N/A | $590.28 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $81.00 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.55 Billion |
| Abeona Therapeutics Inc (ABEO) | $-17.08 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $97.37 Million | -71.81% | 0.35x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $33.54 Million |
| Abivax SA American Depositary Shares (ABVX) | $455.01 Million | -73.87% | 0.28x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $3.59 Billion |
About Adlai Nortye Ltd. American Depositary Shares
Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rect… Read more